How ARPA-H Is Opening New Doors for Small Businesses: Sam Gussman-Toh on Funding, Commercialization, and Breakthrough Health Innovation
BioTalk with Rich BendisShow Notes
In this episode of BioTalk with Rich Bendis, Sam Gussman-Toh, Portfolio Manager for the Small Business Program at ARPA-H, joins the conversation to discuss how the agency is creating new pathways for small businesses developing ambitious health technologies.
Sam explains how the ARPA-H model differs from traditional federal funding programs, with a focus on moonshot health solutions, program manager-led portfolios, milestone-driven contracts, and a strong emphasis on moving technologies toward real-world use. He also discusses how the Small Business Program supports SBIR and STTR performers through Phase I, Phase II, Direct to Phase II, and Fast Track awards.
The conversation highlights how ARPA-H is working with ambitious small businesses, including non-traditional companies and early-stage startups that may be working with the federal government for the first time. Sam also shares how commercialization support is built into the program, including ARPA-H's Entrepreneur-in-Residence partnership with BioHealth Innovation. Through that relationship, BHI EIRs help performers strengthen regulatory strategy, intellectual property planning, go-to-market strategy, reimbursement considerations, and other key commercialization needs.
Sam also discusses ARPA-H's draft Small Business Program solicitation, the upcoming virtual Proposers' Day on June 11, and what companies should know about the application process, topic areas, technical pitches, and future funding opportunities.
Editing and post-production work for this episode was provided by The Podcast Consultant.
Sam Gussman-Toh is Portfolio Manager for the Small Business Program at ARPA-H, where he coordinates and oversees the agency's SBIR/STTR awards and commercialization support services for participating small businesses. Sam joined ARPA-H in 2022 and wrote the agency's first SBIR/STTR solicitation. He has held several roles in the Office of Commercialization and has worked closely with Program Managers to build the agency's commercialization infrastructure and strategy. Previously, Sam designed and managed rapid prototyping programs across agencies in the Department of War. His technical background is in computer science, with interests in computer vision, autonomous robotic systems, and computational pathology.
More from BioTalk with Rich Bendis
In this episode of BioTalk with Rich Bendis, Maureen L. Mulvihill, Ph.D., Founder, President, and CEO of Actuated Medical, discusses the company's 2026 BioHealth Capital Region Crab Trap Competition win and its work advancing medical device innovation from central Pennsylvania. Maureen shares how Actuated Medical grew from a focus on improving patient outcomes through innovative motion into a company with more than $50 million in non-dilutive funding, 43 patents, 9 FDA 510(k) clearances, and FDA-registered, ISO 13485-certified manufacturing infrastructure. Rich and Maureen also discuss the TubeClear system, Actuated Medical's first FDA-cleared device, including the story of the first patient it helped at Walter Reed, and how that experience shaped the company's mission. The episode also explores NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform, including how earlier work in tissue penetration led to brain implant technology, DARPA-supported commercialization, global research use, and the company's next steps toward clinical applications. Maureen also shares what comes next for Actuated Medical, including its focus on NeuroGlider, upcoming visibility at the MedTech Conference in Boston, and her advice to entrepreneurs building medical device companies: persistence matters. Editing and post-production work for this episode was provided by The Podcast Consultant. Maureen L. Mulvihill, Ph.D., is Founder, President, and CEO of Actuated Medical, a medical device company advancing the NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform for neurotechnology, brain therapeutics, and longevity-related medicine. Under her leadership, Actuated Medical has secured more than $50 million in non-dilutive funding, developed a portfolio of 43 patents, achieved 9 FDA 510(k) clearances, and earned two SBA Tibbetts Awards recognizing excellence in commercialization. Dr. Mulvihill serves on the Board of Directors of AdvaMed, the AdvaMed Accel Board, the Life Sciences Pennsylvania Board of Directors, chairs the Industrial Advisory Board for the Penn State Center for Biodevices, and serves on the Kish Bank Regional Advisory Board. She has received more than 35 entrepreneurship and leadership awards, including being named 2020 Life Sciences Pennsylvania CEO of the Year and leading Actuated Medical to First Place in the 2026 BioHealth Capital Region Crab Trap Competition. She earned her Ph.D. from The Pennsylvania State University.
In this episode of BioTalk with Rich Bendis, Ralf Huss, MD, PhD, Managing Director and CEO of BioM Biotech Cluster Development GmbH and spokesperson for the Bavarian Biotechnology Cluster, joins the conversation to discuss Bavaria's biotechnology ecosystem and BioM's role in moving science toward commercialization. Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation. Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM's work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role. The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region. Editing and post-production work for this episode was provided by The Podcast Consultant. Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe's leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.
In this episode of BioTalk with Rich Bendis, Subin Baral, Partner at Ernst & Young LLP and EY-Parthenon Global Life Sciences Deals Leader, joins the conversation to discuss the changing life sciences dealmaking environment and what it means for companies, investors, and regional innovation ecosystems.
In this episode of BioTalk with Rich Bendis, Tammi Thomas, President of TEDCO, joins the conversation to discuss how Maryland is helping entrepreneurs move ideas from research and concept to market.
In this episode of BioTalk with Rich Bendis, Matt Adams, Chief Executive Officer of BrainScope, joins the conversation to discuss how the Rockville-based company is working to bring objective brain function measurement into real-world clinical care.